CNS pen. GPR6 GPCR inverse agonist

oral QD Ph. II candidate for ParkinsonÕs

from 360k cmpd cell-based HTS + opt.

J. Pharmacol. Exp. Ther., Apr. 1, 2021

Cerevance / Takeda California, San Diego, US

Structure of CVN424

The Cerevance/Takeda GPR6 inverse agonist (CVN424) is an oral, once-daily clinical candidate in Ph. II for Parkinson’s disease after completing a Ph. I in healthy volunteers. Its >40 µM…


get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: